Treatment patterns in hormone-sensitive metastatic prostate cancer: data from a referral hospital in Bogota, real-world evidence study
Objective: The objective of the study is to determine through a historical cohort, the characteristics, treatment patterns, and outcomes of a population with hormone-sensitive metastatic cancer at a referral center in Bogota. Method: This was a historical cohort observational study. All patients wit...
Saved in:
| Published in: | Urologia Colombiana Vol. 33; no. 3 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Publicaciones Permanyer
01-07-2024
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Objective: The objective of the study is to determine through a historical cohort, the characteristics, treatment patterns, and outcomes of a population with hormone-sensitive metastatic cancer at a referral center in Bogota. Method: This was a historical cohort observational study. All patients with metastatic hormone-sensitive prostate cancer from 2018 to May 2022 who received androgen deprivation therapy with or without treatment intensification were included through convenience sampling. The distribution of the epidemiological variables of interest, treatment of choice, and survival analysis was performed, as well as the distribution by years of the therapies of choice. Statistical significance was set at p < 0.05. Results: We included 125 hormone-sensitive metastatic prostate cancer (mHSPC) patients with a median age of 73.5 years (confidence interval: 71.48- 75.31), a median PSA of 209 ng/mL, and 90% of patients with synchronous mHSPC. The distribution of high-volume mHSPC was 92% and M1b was 91%. The distribution of castration methods over time revealed that 21% of the patients underwent surgical castration and 79% received pharmacological castration. Since 2018, 40% of patients received androgen deprivation therapies (ADT) exclusively, 30% received treatment with taxanes, and 30% received androgen receptor axis-directed therapies. Trends in treatment distribution from 2018 to 2022 indicated a decline in exclusive ADT use from 41% in 2019 to 16% in 2022. 9% of the patients abandoned treatment. Conclusion: A description of the population of a national reference center for the treatment of hormone-sensitive prostate cancer with demographic characteristics according to global trends was provided. |
|---|---|
| ISSN: | 0120-789X |